All the Active Ingredient Drugs
Angiotensin II Antagonist, Thiazide. Valsartan 80 mg, 160 mg, Hydrochlorothiazide 12.5 mg, 25 mg. CO-DIOVAN 80: F.C. TABS: 28. 1 tab dly. Max. effect within 2-4 wks.
Hypertens. when comb. ther. appropriate.
CO-DIOVAN 160: F.C. TABS: 28. 1 tab dly.
Hypertens., when blood pressure not adequat. controlled by monother. To be used as second-line ther.
C/I: Hypersens. Hypersens. to sulfonamide-derived med. products. 2nd & 3rd trim. of preg. Biliary cirrhos. and cholestasis. Pts. with anuria. Refractor. hypokalaemia, hyponatraemia, hypercalcaemia, and symptomat. hyperuricaemia. Concom. use with aliskiren-contain. products in pts. with diab. mell. or renal impair. (GFR <60 mL/min/1.73m²).
Angiotensin II Antagonist. Valsartan 40, 80 ,160 mg. F.C. TABS.: 28. Hyperten.: 80 mg×1/d most
pts. The antihypertens. effect is
substantial. present within 2 wks. and
max. effects are seen after 4 wks.
In some pts. whose blood press. is not
adequate. control., the dose may be
incr. to 160 mg, or a greater decr. in BP
may be achieved by add. in a thiazide
diuret. See lit.
Heart fail.: 40 mg ×1/d.
Uptitration to 80 mg, 160 mg×2/d
should be done to the highest dose
tolerat. by the pt.
Considerat. should be given to
reducing the dose of concom. diuret.
The max. dly. dose admin. in clin. trials
is 320 mg in divided doses. See lit.
Post-MI.: Achievem. of the target dose
of 160 mg×2/d should be based on the
pt’s tolerab. to valsartan during titrat. If
symptomat. hypotension or renal
dysfunct. occurs, consider. should be
given to a dosage reduct. See lit.
Therapy may be init. as early as 12 hrs.
after a MI . After an initial dose of 20 mg ×2/ d, valsartan ther. should be
titrated to 40 mg, 80 mg, and 160 mg
×2/ d over the next few wks. The start.
dose is provided by the 40 mg divisible
tab.
Tmt. of hypertens.: 80 mg and 160 mg.
Heart fail.: 40 mg, 80 mg and 160 mg.
Tmt. of heart fail. (NYHA class II‐IV) in pts.
who are intoler. of angiotens. Convert.
enzyme inhib. See lit.
Post-myocard. infarction (40 mg, 80 mg
and 160 mg): Indicat. to improve survival follow. myocard. infarct. in clinical. stable pts. with signs, sympt. or radiolog. evidence
of left ventric. fail. and/or with left
ventric. systolic dysfunct. See lit.
C/I: Known hypersens. to valsartan or to
any of the excip. Preg., and lact.
Sev. hepatic impair., cirrhosis, biliary
obstruct. Concom. use of angiotensin
recept. antagonists (ARBs) ‐ includ.
valsartan ‐ or of ACEIs with aliskiren is
contraind. in pts. with diab. mell. or renal
impair.(GFR < 60 ml/min/1.73 m²). See
lit.
Angiotensin II Antagonist, Plain Combinations with Dihydropyridine Derivatives. Amlodipine Besylate 5 mg, 10 mg, Valsartan 80 mg, 160 mg. COATED TABS.: 28 x 5 mg/80 mg,
5 mg/160mg; 10 mg/160 mg.
1 tab dly. Individ. dosetitrat. with
components recommend. before changingto fixed dose comb.Max. dose is 10/320 mg.
Tmt. of essential hypertens., for pts.
whose blood pressure is not adeq.
controlled on monotherapy.
C/I: Hypersens.toamlodopine, valsartan,
todihydropyridinederivat.; Severe hep.
impair., cholestasis; Severe renal impair.
and pts. underg. dialysis;
Preg.; Concom. use of ARBs or ACEIs with
aliskiren in pts. with diabet.
Angiotensin II Antagonist, Other Combinations. Sacubitril 24, 49, 97 mg, Valsartan (as sodium salt complex) 26, 51, 103 mg. F.C. TABS: 28×50 mg, 56×100 mg, 56×200 mg. Init. dose: 1 tab (100 mg)×2/d, The dose should be doubled (in certain situation.) after 2-4 wks. to the target maint. dose of 1 tab. of 200 mg twice dly., as tolerated by the pt. See lit.
Tmt. of heart fail. (NYHA class II-IV) in pts. with syst. dysfunc. This formulation has been shown to reduce the rate of cardiovasc. death and heart fail. hospitalis. compared to ACE inhib. therapy.
C/I: Hypersens. Concom. use with ACE inhib. , ust not be admin. until 36 hrs. after discount. ACE inhib. ther. Known hist. of angioed.related to prev.ACE inhib. or ARB therapy. Hered. or idiopath. angioed. Concom. use with aliskiren-contain. med. products in pts. with diabetes mell. or in pts. with renal impair. (eGFR <60 ml/min/1.73 m2). Severe hep. impair., biliary cirrhosis and cholestasis. 2nd, 3rd trimes. of preg. Pts. with serum K+ level >5.4 mmol/l or with SBP <100 mmHg.
Angiotensin II Antagonist, Calcium Channel Blocker. Amlodipine Besylate 5 mg, 10 mg, Valsartan 80 mg, 160 mg. F.C. TABS: 14, 28 x 5 mg/80 mg, 5 mg/160 mg, 10 mg/160 mg. 1 tab. dly. with/ without food. Individ. dose titrat. recommend. bef. change to fixed dose comb. See lit.
Indicated for pts. whose blood pressure is not adequat. controlled on monother.
C/I: Hypersens. to the active substance., or to dihydropyridine derivat.
Sev. hep. impair., biliary cirrhos. or cholestasis.
Concom. use with aliskiren-contain. products in pts. with diabetes mell. or renal impair. (GFR <60 ml/min/1.73 m²).
2nd and 3rd trimesters of preg.
Severe hypotens.
Shock (include. cardiogen. shock).
Obstruct. of the outflow tract of the left ventricle (e.g. hypertrop. obstruct. cardiomyopathy and high grade aortic stenosis).
Haemodynamic. unstable HF after acute MI.
Angiotensin II Antagonist, Other Combinations. Sacubitril 24 mg, 49 mg, 97mg, Valsartan 26 mg, 51 mg, 103 mg. FC Tab.28 x50mg/ 56X100 mg/56X200 mg
Start. dosage is gen. 50 mg or 100 mg twice/d. Target dosage is gen. 200 mg twice/d. See lit.
Tmt. of heart fail. (NYHA class II-IV) in pts. with systol. dysfunct..
This med. prod. has been shown to red. the rate of CV death and HF hosp. compared to angiotensin converting enzyme (ACE) inhib. ther.
C/I: hypersens/Concomit. use with ACE inhib. Wait 36 hs. after taking last ACEI dose before starting tmt. with this med. prod.
/ Known hist. of angioedema rel. to ACE inhib. or an angiotensin receptor blocker (ARB) ther., hered. or unknown cause.
/ Concom. use with aliskiren-containing med. prod. in pts. with diabetes mellitus or with renal impaim.
/ Severe liver dis.
/Second and third trim. of pregn.